Checkpoint inhibitors (pembrolizumab · nivolumab · ipilimumab)
Immune checkpoint inhibitor
Acute interstitial nephritis with long latency.
AIN
ModerateOpen →
PD-1 immune checkpoint inhibitor
Tislelizumab
Tevimbra · PD-1 inhibitor
A PD-1 blocker whose kidney risk is the class-typical rare immune-mediated interstitial nephritis.
Moderatecheckpoint-immunotherapy · approved 2024
Advanced or metastatic esophageal squamous cell carcinoma (second-line, monotherapy)Advanced or metastatic esophageal squamous cell carcinoma (first-line, with chemotherapy)Advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (with chemotherapy, PD-L1+)
Signature kidney injury
Acute Interstitial Nephritis
Representative incidence2%
Drug-specific renal data are sparse: the registrational ESCC trials (RATIONALE-302, RATIONALE-306) did not report nephritis as a notable adverse event, and no tislelizumab-specific biopsy series exists. Reasoning from the PD-1 class, immune-mediated acute interstitial nephritis (the class signature) is uncommon at roughly 1-3% of treated patients, while any-cause AKI in real-world ICI cohorts is far higher (16-17%) but mostly prerenal/non-immune rather than true ICI-nephritis.
Source: No tislelizumab-specific renal incidence is published; the ~1-3% AIN estimate is extrapolated from PD-1-class cohorts. In a single-center ICI cohort, 16.5% developed AKI but only ~2% (6/309) had biopsy/clinically attributed interstitial nephritis (Meraz-Munoz et al., J Immunother Cancer 2020, PMID 32601079); in an anti-PD-1 melanoma cohort, 17% had AKI but only 3.3% had AIN, most AKI being prerenal (Stein et al., NDT 2021, PMID 32941608).
Toxicity fingerprint
Tap a signature to trace where it strikes the nephron.
0%incidence
SeverityModerate
ReversibilityPartially reversible
Evidence0 refs
Nephron map
Glomerulus
Vasculature / Endothelium
Distal Tubule / Collecting Duct
InterstitiumSupporting tissue around the tubules
Acute Interstitial Nephritis
Immune-mediated inflammation of the renal interstitium — the signature kidney injury of checkpoint inhibitors.
Mechanism of kidney injury
The dominant kidney lesion of PD-1 blockade is immune-mediated acute interstitial nephritis: loss of peripheral tolerance unmasks autoreactive T cells, producing a granulomatous or lymphocytic tubulointerstitial infiltrate, often with a delayed onset weeks to months into therapy and frequently concurrent with extrarenal immune-related adverse events. Less commonly, checkpoint blockade is associated with de novo or relapsing glomerular disease (minimal change, membranous, pauci-immune) and rare thrombotic microangiopathy. Tislelizumab's reduced FcγR engagement is a theoretical T-cell-sparing advantage but has not been shown to lower renal immune-related toxicity. Much AKI in these patients is not drug-immune at all but prerenal/hemodynamic (volume depletion, concurrent nephrotoxins, RAAS inhibitors).
Clinical presentation
Typically a subacute, often asymptomatic rise in serum creatinine detected on routine labs, sometimes with sterile pyuria, low-grade eosinophiluria, or subnephrotic proteinuria. Overt oliguria is uncommon. AIN is frequently accompanied by other immune-related adverse events (rash, colitis, hepatitis, thyroiditis), which is an important diagnostic clue. Glomerular involvement may present with nephrotic-range proteinuria or hematuria.
Anticancer mechanism
Tislelizumab is a humanized IgG4-variant monoclonal antibody that binds programmed cell death protein 1 (PD-1) on T cells, blocking its engagement by PD-L1/PD-L2 and releasing the brake on cytotoxic T-cell responses against tumor cells. It is uniquely Fc-engineered to minimize binding to FcγRI on macrophages, reducing antibody-dependent phagocytosis of activated effector T cells. Approved in the US (Tevimbra) for esophageal squamous cell carcinoma and gastric/GEJ adenocarcinoma.
Management
For immune-mediated AIN: hold tislelizumab, exclude prerenal and obstructive causes, and consider kidney biopsy when the diagnosis is unclear. Grade 2-3 nephritis is treated with corticosteroids (e.g., prednisone 0.5-1 mg/kg/day, higher for severe cases) with a slow taper; discontinue offending co-medications (PPIs/NSAIDs). Permanently discontinue for grade 3-4 or recurrent immune-mediated nephritis. Rechallenge after resolved low-grade AIN can be considered cautiously with monitoring. Prerenal AKI is managed with volume optimization and removal of contributing agents rather than steroids.
Risk factors
- Concurrent or prior immune-related adverse events (strongest associated risk)
- Pre-existing hypertension
- Combination with other nephritis-associated drugs (PPIs, NSAIDs, antibiotics)
- RAAS inhibitor or diuretic use (predisposes to prerenal AKI)
- Pre-existing chronic kidney disease
- Higher cumulative checkpoint-inhibitor exposure
Prevention
- Baseline and periodic serum creatinine and urinalysis monitoring throughout therapy
- Review and minimize concomitant nephritis-associated drugs (PPIs, NSAIDs)
- Maintain euvolemia; reassess RAAS inhibitors and diuretics
- Early nephrology referral and low threshold for kidney biopsy when AKI develops
- Hold drug and evaluate before attributing AKI to a benign cause
Note · Tislelizumab has no published kidney-specific case series or biopsy data; this profile reasons transparently from the PD-1 checkpoint-inhibitor class and from registrational ESCC trial safety data, which did not flag nephritis as prominent. The renal signature is assigned as class-typical immune-mediated acute interstitial nephritis, with the honest caveat that most real-world AKI in these patients is prerenal rather than drug-immune.
Clinical depth
Renal dose adjustment
No starting-dose adjustment for renal impairment is recommended; tislelizumab is given as a fixed 200 mg IV every 3 weeks. As a ~150 kDa monoclonal antibody it is cleared by reticuloendothelial proteolysis, not the kidney, so mild-to-moderate renal impairment does not alter exposure. Data in severe impairment/dialysis are limited. Dose modification is event-driven (hold/discontinue for immune-mediated nephritis), not pharmacokinetic.
Dialyzability & ESKD dosing
Not dialyzable. Large IgG4 monoclonal antibodies are not removed by hemodialysis or peritoneal dialysis; timing relative to dialysis is irrelevant.
Differential diagnosis
Distinguish true immune-mediated AIN from the much more common prerenal/hemodynamic AKI (volume depletion, sepsis, contrast, cardiorenal). Other considerations: concurrent PPI/NSAID/antibiotic-induced AIN, tumor-related obstruction, hypercalcemia, and checkpoint-associated glomerulonephritis or thrombotic microangiopathy. Concurrent extrarenal immune-related adverse events and sterile pyuria favor AIN; bland sediment with a clear hemodynamic trigger favors prerenal. Kidney biopsy is the reference standard when management hinges on the distinction.
Monitoring
- Serum creatinine/eGFR at baseline and before each cycle
- Urinalysis for proteinuria, pyuria, and hematuria
- Surveillance for concurrent immune-related adverse events (thyroid, hepatic, GI, skin)
- Electrolytes (including Mg, K) if other irAEs or losses present
- Trend creatinine after any drug hold or steroid course to confirm recovery
Key trials & series
- RATIONALE-302 (NCT03430843): phase 3, second-line tislelizumab vs chemotherapy in advanced/metastatic ESCC; OS benefit, fewer grade 3+ treatment-related AEs (18.8% vs 55.8%)
- RATIONALE-306 (NCT03783442): phase 3, first-line tislelizumab + chemotherapy vs placebo + chemotherapy in advanced/metastatic ESCC; OS 17.2 vs 10.6 months
Clinical pearls
- Tislelizumab is Fc-engineered to minimize FcγRI binding (less macrophage-mediated T-cell clearance) — a theoretical efficacy/safety tweak, but no evidence it reduces renal immune toxicity versus other PD-1 agents.
- Most AKI on any PD-1 agent is NOT drug-immune nephritis — it is prerenal/hemodynamic; reserve steroids for genuine immune-mediated AIN.
- AIN classically appears weeks-to-months in and travels with other immune-related adverse events; look for a rash/colitis/thyroiditis clue.
- Co-prescribed PPIs and NSAIDs are frequent AIN cofactors — review and stop them when checkpoint nephritis is suspected.
- Paradoxically, biopsy-confirmed checkpoint AIN may signal a favorable tumor response, but it still warrants drug hold and steroids.
Beyond the kidney
Class-level context for the major non-renal toxicities of pd-1 immune checkpoint inhibitors.
Endocrine
Thyroiditis, hypophysitis, diabetes
- Thyroiditis, hypophysitis, type-1 diabetes
Gastrointestinal
Diarrhea, colitis, mucositis, perforation
- Immune colitis
Hepatic / Liver
Transaminitis, hepatitis, VOD/SOS
- Immune hepatitis
Pulmonary
Pneumonitis, ILD, effusions, hypertension
- Pneumonitis
Dermatologic
Rash, HFS, SJS/TEN, vitiligo
- Rash, vitiligo, rarely SJS/TEN
Evidence
5 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkTislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.Shen L, Kato K, Kim SB, et al. · Journal of Clinical Oncology 2022 · PMID 35442766Landmark registrational phase 3 trial supporting US approval; establishes the safety profile, with substantially fewer grade 3+ treatment-related adverse events than chemotherapy and no prominent renal signal.PMIDTislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study.Xu J, Kato K, Raymond E, et al. · The Lancet Oncology 2023 · PMID 37080222First-line phase 3 registrational trial; large global safety dataset where nephritis was not among the notable treatment-related adverse events, supporting a low direct renal toxicity estimate.PMIDAcute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes.Meraz-Munoz A, Amir E, Ng P, et al. · Journal for ImmunoTherapy of Cancer 2020 · PMID 32601079Class cohort grounding the incidence reasoning: 16.5% AKI overall but only ~2% biopsy/clinically attributed interstitial nephritis; AKI linked to concurrent irAEs and hypertension.PMIDAcute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort.Stein C, Burtey S, Mancini J, et al. · Nephrology Dialysis Transplantation 2021 · PMID 32941608Anti-PD-1-specific cohort showing 17% AKI but only 3.3% AIN, with most AKI prerenal and favored by RAAS inhibitors — the basis for the prerenal caveat in this profile.PMIDMortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy.Baker ML, Yamamoto Y, Perazella MA, et al. · Journal for ImmunoTherapy of Cancer 2022 · PMID 35354588Supports the differential/pearls: ICI-AIN presents with higher peak creatinine yet better survival than non-AIN AKI, underscoring the value of distinguishing immune nephritis from prerenal AKI.